The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Rhythm Pharmaceuticals Inc shares valued at $457,663 were sold by Cramer Pamela J. on Apr 29 ’25. At $65.09 per share, Cramer Pamela J. sold 7,031 shares. The insider’s holdings dropped to 19,209 shares worth approximately $1.19 million following the completion of this transaction.
Also, Mazabraud Yann sold 6,745 shares, netting a total of over 438,946 in proceeds. Following the sale of shares at $65.08 each, the insider now holds 37,655 shares.
Before that, YANN MAZZABRAUD had added 6,745 shares to its account. In a trade valued at $434,445, the Officer bought Rhythm Pharmaceuticals Inc shares for $64.41 each.
As published in a research note from BofA Securities on April 07, 2025, Rhythm Pharmaceuticals Inc [RYTM] has been rated up from a Neutral to a Buy and the price target has been revised to $63. As of January 02, 2025, Jefferies has initiated its “Buy” rating for RYTM. Earlier on December 20, 2024, Oppenheimer initiated its rating. Their recommendation was “an Outperform” for RYTM stock.
Analyzing RYTM Stock Performance
During the last five days, there has been a drop of approximately -0.85%. Over the course of the year, Rhythm Pharmaceuticals Inc shares have jumped approximately 10.54%. Shares of the company reached a 52-week high of $66.09 on 05/02/25 and a 52-week low of $45.90 on 04/07/25.
Support And Resistance Levels for Rhythm Pharmaceuticals Inc (RYTM)
According to the 24-hour chart, there is a support level at 60.21, which, if violated, would cause prices to drop to 58.55. In the upper region, resistance lies at 63.39. The next price resistance is at 64.91. RSI (Relative Strength Index) is 53.18 on the 14-day chart, showing neutral technical sentiment.
